IMUX serves as the official ticker symbol for Immunic, Inc., a late-stage clinical biopharmaceutical enterprise specializing in the discovery and development of novel oral small-molecule therapies for chronic inflammatory and autoimmune diseases, such as multiple sclerosis and ulcerative colitis. The symbol identifies the company's common stock as it trades publicly on the Nasdaq Capital Market. Additionally, within specialized contexts, the acronym or identifier represents the unique corporate security designation assigned to track the firm's financial market performance and equity capitalization.